Triple Negative Breast Cancer Clinical Trials in Dallas, Texas

9 studies are recruiting for triple negative breast cancer in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

   This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and d…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - DFW ( Site 8000), Dallas, Texas

   Locations

   311 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06393374 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   UT Southwest Simmons Cancer Center, Dallas, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mary Crowley Cancer Research, Dallas, Texas

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

4. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Texas Oncology, P.A., Dallas, Texas

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

5. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Southwestern, Dallas, Texas

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

6. A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

   The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Texas Oncology - DFW, Dallas, Texas

   Locations

   16 in total

   Run by

   Gilead Sciences

   See if you can join NCT06926920 on ClinicalTrials.gov

7. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

   A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dren Investigational Site, Dallas, Texas

   Locations

   10 in total

   Run by

   Dren Bio

   See if you can join NCT06999187 on ClinicalTrials.gov

8. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov

9. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

   A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Dallas, Dallas, Texas

   Locations

   2 in total

   Run by

   Hefei TG ImmunoPharma Co., Ltd.

   See if you can join NCT05746897 on ClinicalTrials.gov